Senores Pharmaceuticals Limited (“SPL”), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (“SPI”), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (‘ANDAs’) from Dr. Reddy’s Laboratories and its applicable affiliates (BSE: 500124 | NSE: DRREDDY | NYSE: RDY |
Senores Pharmaceuticals Limited (‘Senores’ or ‘SPL’) has today inaugurated and commenced manufacturing activities at its greenfield Active Pharmaceutical Ingredient (API) plant located at Survey No. 1503, Rajpur, Kadi, Mehsana - 382 715, Gujarat. Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric
Granules India Limited (BSE: 532482, NSE: GRANULES) today announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services.
Senores Pharmaceuticals Limited (‘SPL’), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (‘SPI’), has signed an agreement today to acquire the USFDA-approved Abbreviated New Drug Application (‘ANDA’) for ‘Roflumilast’ 250 mcg and 500 mcg tablets from Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International
OSAKA, Japan – The countdown has begun for MEDICAL JAPAN 2025 OSAKA, Western Japan’s leading medical and healthcare trade show, taking place from March 5-7, 2025, at INTEX Osaka, where industry professionals, thought leaders, and innovators will gather to showcase cutting-edge technologies, foster collaboration, and
Anindith Reddy, Managing Director of Wadi Surgicals (Enliva) & Member of IRGMA The Indian medical device market though growing rapidly, is driven by 70-80% imports from countries such as the US, China, and Germany. The medical device sector in the country was estimated at 11 billion
Revenue from operations at Rs 1,963 Cr, up 17.7% YoY EBITDA margins at 18.4% with EBITDA up 23.2% YoY PAT at 156Cr, up 30.3% YoY Domestic business sales at 888 Cr, up 12.0% YoY International business sales at 1,075 Cr, up 23.0% YoY Emcure Pharmaceuticals
Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate Capsules in strengths
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2024. Financial Summary (All numbers in INR Mn., except Margins) QUARTERLY CONSOLIDATED FINANCIALS Q3FY25 Q2FY25 Growth (QoQ) Q3FY24 Growth (YoY) Revenue from Operations 11,377 9,666 18% 11,556 -2% EBITDA 2,303 2,033 13% 2,505 -8% EBITDA % 20% 21% 22% PAT 1,176 972 21% 1,257 -6% PAT % 10% 10% 11% Financial and Business Summary for Q3FY25 The Company voluntarily paused
Senores Pharmaceuticals Ltd. has reported revenue of ₹288 Cr during 9MFY25 ending 31st December,2024, reflecting a robust growth of 157%. The exceptional financial performance underscores the company’s strong business strategies and operational excellence. Key Highlights Total Revenue is 288 Cr which is 157% increase PAT after
